The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

There is a growing body of evidence supporting the use of epigenetic therapies in the treatment of multiple myeloma. We show the novel HDAC inhibitor CHR-3996 induces apoptosis in myeloma cells at concentrations in the nanomolar range and with apoptosis mediated by p53 and caspase pathways. In addit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Smith, Emma M., Zhang, Lei, Walker, Brian A., Davenport, Emma L., Aronson, Lauren I., Krige, David, Hooftman, Leon, Drummond, Alan H., Morgan, Gareth J., Davies, Faith E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2013
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4627310/
https://ncbi.nlm.nih.gov/pubmed/26015393
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge